HLB Pharmaceutical (047920) Fundamentals 2026 — P/E 70.4x, Revenue Analysis | SniperIQ
HLB Pharmaceutical (047920) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩262.4B, trading at ₩8000.00 on the KOE. This SniperIQ fundamentals page covers HLB Pharmaceutical's valuation (P/E 70.4x, P/B 1.7x), profitability (net margin 1.6%), revenue (₩205.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is HLB Pharmaceutical's market cap?
HLB Pharmaceutical (047920) has a market capitalization of approximately ₩262.4B, trading at ₩8000.00 on the KOE. Market cap moves with the live share price.
What is HLB Pharmaceutical's P/E ratio?
HLB Pharmaceutical's trailing twelve-month P/E ratio is 70.4x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is HLB Pharmaceutical?
HLB Pharmaceutical runs a net profit margin of 1.6%, a gross margin of 46.2%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HLB Pharmaceutical generate?
HLB Pharmaceutical reported revenue of ₩205.6B for fiscal year 2025, with net income of ₩4.6B and earnings per share (EPS) of 140.86. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does HLB Pharmaceutical pay a dividend?
HLB Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is HLB Pharmaceutical financially healthy?
HLB Pharmaceutical carries a debt-to-equity ratio of 0.13x and a current ratio of 1.90x, with a market beta of 1.83. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HLB Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HLB Pharmaceutical (047920) the key facts are: market cap ₩262.4B, P/E 70.4x, revenue ₩205.6B, 52-week range 6000-22250. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track HLB Pharmaceutical's full fundamentals live
Get HLB Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.